CA2546057A1 - Procede permettant d'ameliorer l'efficacite de medicaments therapeutiques radiomarques - Google Patents
Procede permettant d'ameliorer l'efficacite de medicaments therapeutiques radiomarques Download PDFInfo
- Publication number
- CA2546057A1 CA2546057A1 CA002546057A CA2546057A CA2546057A1 CA 2546057 A1 CA2546057 A1 CA 2546057A1 CA 002546057 A CA002546057 A CA 002546057A CA 2546057 A CA2546057 A CA 2546057A CA 2546057 A1 CA2546057 A1 CA 2546057A1
- Authority
- CA
- Canada
- Prior art keywords
- drug
- ibritumomab tiuxetan
- yttrium
- moiety
- labeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 100
- 229940079593 drug Drugs 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000001225 therapeutic effect Effects 0.000 title claims description 7
- 239000002534 radiation-sensitizing agent Substances 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 17
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims description 33
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims description 33
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 26
- 230000000637 radiosensitizating effect Effects 0.000 claims description 26
- 239000002738 chelating agent Substances 0.000 claims description 21
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 18
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 13
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 13
- 230000002285 radioactive effect Effects 0.000 claims description 13
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 12
- 239000013522 chelant Substances 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 239000011630 iodine Substances 0.000 claims description 10
- 229910052742 iron Inorganic materials 0.000 claims description 9
- 239000002502 liposome Substances 0.000 claims description 8
- 229910017052 cobalt Inorganic materials 0.000 claims description 7
- 239000010941 cobalt Substances 0.000 claims description 7
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 7
- 230000008685 targeting Effects 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000000693 micelle Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- RIWAPWDHHMWTRA-UHFFFAOYSA-N 1,2,3-triiodobenzene Chemical group IC1=CC=CC(I)=C1I RIWAPWDHHMWTRA-UHFFFAOYSA-N 0.000 claims description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 4
- 229920001222 biopolymer Polymers 0.000 claims description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 229910000085 borane Inorganic materials 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 3
- 150000002602 lanthanoids Chemical class 0.000 claims description 3
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 claims description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical group OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims description 2
- 230000005855 radiation Effects 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229910003317 GdCl3 Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- MEANOSLIBWSCIT-UHFFFAOYSA-K gadolinium trichloride Chemical compound Cl[Gd](Cl)Cl MEANOSLIBWSCIT-UHFFFAOYSA-K 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000000163 radioactive labelling Methods 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960005267 tositumomab Drugs 0.000 description 2
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical group [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52847303P | 2003-12-11 | 2003-12-11 | |
US60/528,473 | 2003-12-11 | ||
PCT/IB2004/004428 WO2005056058A2 (fr) | 2003-12-11 | 2004-12-13 | Procede permettant d'ameliorer l'efficacite de medicaments therapeutiques radiomarques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2546057A1 true CA2546057A1 (fr) | 2005-06-23 |
Family
ID=34676848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002546057A Abandoned CA2546057A1 (fr) | 2003-12-11 | 2004-12-13 | Procede permettant d'ameliorer l'efficacite de medicaments therapeutiques radiomarques |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1691838A2 (fr) |
JP (1) | JP2007528874A (fr) |
KR (1) | KR20060118542A (fr) |
CN (1) | CN101031319A (fr) |
AU (1) | AU2004296621A1 (fr) |
BR (1) | BRPI0417517A (fr) |
CA (1) | CA2546057A1 (fr) |
CR (1) | CR8439A (fr) |
EC (1) | ECSP066618A (fr) |
IL (1) | IL175674A0 (fr) |
MX (1) | MXPA06006683A (fr) |
NO (1) | NO20063207L (fr) |
RU (1) | RU2006124510A (fr) |
WO (1) | WO2005056058A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI568453B (zh) * | 2011-11-22 | 2017-02-01 | 原創生醫股份有限公司 | 具有螯合型複合微胞之藥物載體及其應用 |
CN106975078B (zh) * | 2017-03-31 | 2020-11-10 | 国家纳米科学中心 | 一种包含多钨酸钆的纳米材料作为增敏剂的用途 |
WO2024013272A1 (fr) * | 2022-07-13 | 2024-01-18 | Universite De Montpellier | Thérapie combinée avec des nanoparticules et des produits radiopharmaceutiques |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR022404A1 (es) * | 1999-01-25 | 2002-09-04 | Photogen Inc | Metodo y agentes para la terapia de radiacion mejorada |
AU2001249608A1 (en) * | 2000-03-28 | 2001-10-08 | Beth Israel Deaconess Medical Center | Bladder cancer-specific peptides for diagnosis and therapy |
MXPA03006771A (es) * | 2001-01-29 | 2004-05-05 | Idec Pharma Corp | Anticuerpos modificados y metodos de uso. |
CA2494372C (fr) * | 2002-08-15 | 2013-05-28 | Human Genome Sciences, Inc. | Anticorps se fixant de facon immunospecifique a des recepteurs trail |
-
2004
- 2004-12-13 RU RU2006124510/15A patent/RU2006124510A/ru not_active Application Discontinuation
- 2004-12-13 WO PCT/IB2004/004428 patent/WO2005056058A2/fr active Search and Examination
- 2004-12-13 CA CA002546057A patent/CA2546057A1/fr not_active Abandoned
- 2004-12-13 AU AU2004296621A patent/AU2004296621A1/en not_active Abandoned
- 2004-12-13 KR KR1020067011322A patent/KR20060118542A/ko not_active Application Discontinuation
- 2004-12-13 CN CNA2004800369951A patent/CN101031319A/zh active Pending
- 2004-12-13 JP JP2006543664A patent/JP2007528874A/ja not_active Withdrawn
- 2004-12-13 BR BRPI0417517-4A patent/BRPI0417517A/pt not_active IP Right Cessation
- 2004-12-13 MX MXPA06006683A patent/MXPA06006683A/es unknown
- 2004-12-13 EP EP04817629A patent/EP1691838A2/fr not_active Withdrawn
-
2006
- 2006-05-16 IL IL175674A patent/IL175674A0/en unknown
- 2006-06-07 CR CR8439A patent/CR8439A/es unknown
- 2006-06-08 EC EC2006006618A patent/ECSP066618A/es unknown
- 2006-07-10 NO NO20063207A patent/NO20063207L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL175674A0 (en) | 2006-09-05 |
WO2005056058A3 (fr) | 2006-04-13 |
AU2004296621A1 (en) | 2005-06-23 |
WO2005056058A2 (fr) | 2005-06-23 |
KR20060118542A (ko) | 2006-11-23 |
RU2006124510A (ru) | 2008-01-20 |
CN101031319A (zh) | 2007-09-05 |
BRPI0417517A (pt) | 2007-03-06 |
CR8439A (es) | 2006-12-07 |
EP1691838A2 (fr) | 2006-08-23 |
JP2007528874A (ja) | 2007-10-18 |
NO20063207L (no) | 2006-07-10 |
ECSP066618A (es) | 2006-10-25 |
MXPA06006683A (es) | 2006-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2247069T3 (es) | Liposomas terapeuticos radioactivos. | |
EP1245031B1 (fr) | Procede servant a produire actinium-225 et ses radionucleides de filiation | |
JP5468597B2 (ja) | 軟組織疾患の放射線治療におけるトリウム−227を用いた医薬組成物、複合体及びその調製方法、並びにキット | |
US6670456B2 (en) | Actinium-225 complexes and conjugates for targeted radiotherapy | |
AU2002306598A1 (en) | Actinium-225 complexes and conjugates for targeted radiotherapy | |
US20060228297A1 (en) | Thorium-227 for use in radiotherapy of soft tissue disease | |
Steffen et al. | Biodistribution of 211At labeled HER-2 binding affibody molecules in mice | |
CA2381123C (fr) | Complexes et conjugat d'actinium-225 pour radio-immunotherapie | |
CA2546057A1 (fr) | Procede permettant d'ameliorer l'efficacite de medicaments therapeutiques radiomarques | |
US20060127308A1 (en) | Method to improve the efficacy of therapeutic radiolabeled drugs | |
JP3794517B2 (ja) | 腫瘍診断剤 | |
Pagano et al. | Radiopharmaceuticals for bone metastases | |
JP4339846B2 (ja) | 腫瘍治療剤 | |
Soloway et al. | 10B+ n,+[nB]+ 7Li (0.87 MeV)+ a (1.52 MeV). tn Table 1. | |
Norman | with Yttrium Macrocycles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |